Phaseline

Companies › Azure Biotech

Azure Biotech: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Genitourinary; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Lasofoxifene Tartrate (AZU-101)
Estrogen receptor modulator
ESR2, ESR1Phase 2Vulvo Vaginal Atrophy (VVA)Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06197568Lasofoxifene Tartrate (AZU-101)Phase 2Vulvo Vaginal Atrophy (VVA)GenitourinaryDec 2026

Targets

ESR2 (1) ESR1 (1)

Companies with the same targets

Pfizer Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair LeonaBio AstraZeneca Roche Eurofarma Laboratorios Eli Lilly Shanghai Best-Link Bioscience Stemline Therapeutics Atossa Therapeutics

Companies built like this

Tioga Pharmaceuticals Gesynta Pharma Suzhou Sanegene Bio R1 Therapeutics Prokrea BCN

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.